Advertisement

Topics

Rubius Therapeutics Closes $120M Financing, Plans Trials Next Year

06:06 EDT 21 Jun 2017 | Genetic Engineering News

Rubius Therapeutics said today it has raised $120 million in a “highly” oversubscribed private financing to support its development of red-cell therapeutics for multiple therapeutic areas, with plans to launch clinical trials in humans next year. Rubius said it will use proceeds of the financing toward accelerating its Red-Cell Therapeutics™ (RCT™) product portfolio, expanding its management team, and advancing its red-cell therapeutics into the clinic. The company has developed technology to grow, genetically engineer, and mature long-circulating red cell therapeutics, saying it has generated more than 200 prototypes to date. The RCT platform is designed to allow Rubius to express enzymes, agonists, antagonists, binders, and combinations in their natural conformation on or inside of red cells. The company says RCTs exhibit fundamentally unique biology and have been engineered to replace missing enzymes for patients living with a variety of rare diseases, to kill tumors , and upregulate ...

Original Article: Rubius Therapeutics Closes $120M Financing, Plans Trials Next Year

NEXT ARTICLE

More From BioPortfolio on "Rubius Therapeutics Closes $120M Financing, Plans Trials Next Year"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...